Indeed, in a phase 1b clinical trial assessing the therapeutic benefit of systemic CD40L blockade in RA, a CD40L-binding protein VIB4920 significantly decreased disease activity and demonstrated an acceptable safety profile (72). Here, CD40LG is linked to rheumatoid arthritis.